Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares

(Image credit: AdobeStock/Golden House Images)

Sanaregen Vision Therapeutics has made an announcement inviting prospective investors to reserve shares of stock ownership. This comes as the company prepares to launch its equity crowdfunding campaign on StartEngine. The goal of this funding is to continue current clinical work, support clinical trial pipelines, and scale business operations.

Sanaregen Vision Therapeutics is developing its lead investigational product, SVT-001. This therapeutic candidate is under clinical evaluation for the treatment of degenerative retinal diseases, which include macular degeneration, geographic atrophy, and retinitis pigmentosa. Under an Investigational New Drug Application (IND) with the FDA, early clinical evidence from the company’s proof-of-concept study showed meaningful improvements in visual acuity and retinal function without any adverse events. Sanaregen has received FDA clearance to escalate dosing and is preparing for a Phase I/II trial.¹

Sanaregen Vision Therapeutics, Inc. is now accepting reservations on the StartEngine platform from prospective investors that wish to purchase common stock in the company. If the Regulation CF is approved, investment into Sanaregen will be used to aid in funding the Phase I/II study.¹

About Sanaregen Vision Therapeutics

Sanaregen Vision Therapeutics, Inc. is a clinical-stage biopharmaceutical research and development company that is developing regenerative medicine treatments designed to effectively treat degenerative retinal diseases. With creative trial design, iterative development, and platform technology with multimodal capabilities, the company says it creates potential for accelerated approvals and first-to-market positioning.¹

Reference:

1. Sanaregen Vision Therapeutics initiates crowdfunding and invites prospective investors to reserve stock on StartEngine. Sanaregen Vision Therapeutics. June 26, 2025. Accessed June 27, 2025. https://www.einpresswire.com/article/825842949/sanaregen-vision-therapeutics-initiates-crowdfunding-and-invites-prospective-investors-to-reserve-stock-on-startengine